

DATE: March 15, 2003

SHEET 1 of 3

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

6789.US.03

SERIAL NO.

(not yet assigned)

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))

APPLICANT(S)

M. D. Cowart, et al.

FILING DATE

September 5, 2003

GROUP

(not yet assigned)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
FB	A1	5,792,768	08/11/98	Kulagowski et al.			
FB	A2	3,472,854	10/14/69	Archer/Sterling			
FB	A3	5,714,498	02/03/98	Kulagowski et al.			
FB	A4	3,362,956	01/09/68	Archer			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC- ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO
FB	B1	98/31368	07/23/98	WO			
	B2	02/88093	07/11/02	WO			
	B3	00/23056	04/27/00	WO			
	B4	0 882 718	12/09/98	EP			
	B5	0 468 884	07/24/91	EP			
	B6	2 154 605	09/14/99	ES			X

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

FB	C1	Andersson, K. et al., "Physiology of penile erection," <i>Physiol. Rev.</i> 75:191-236 (1995)
	C2	Bendele, A.M. et al., "Anti-Inflammatory Activity of Pergolide, a Dopamine Receptor Agonist," <i>Journal of Pharmacology and Experimental Therapeutics</i> 259(1):169-175 (1991)
	C3	Chen, F.F. et al., "Effects of dopamine, Apomorphine, -Hydroxybutyric Acid, Haloperidol and Pimozide on Reflex Bradycardia in Rats," <i>Journal of Pharmacology and Experimental Therapeutics</i> 214(2):427-432 (1980)
	C4	DeGroat, W. et al., "Neural Control of Penile Erection, in : Nervous control of urogenital system," <i>Hardwood Academic Publishers, Chur, Switzerland, Vol. 3 (ed. Maggi, C.):467-524 (1993)</i>
	C5	Dula, E. et al., "Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction," <i>Urology</i> 56:130-135 (2000)

EXAMINER

F. Bernhardt

DATE CONSIDERED

9/30/05

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)

DATE: March 12, 2003

SHEET 2 of 3

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98 (b))	ATTY. DOCKET NO. 6789.US.03	SERIAL NO. (not yet assigned)
	APPLICANT(S) M. D. Cowart, et al.	
	FILING DATE September 5, 2003	GROUP (not yet assigned)


U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

DOCUMENT NUMBER	PUBLICA- TION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

<i>FB</i> 	C6	Hahn, R.A. et al., "Primate Cardiovascular Responses Mediated by Dopamine Receptors: Effects of N, N-di-n-Propylidopamine and LY171555," Journal of Pharmacology and Experimental therapeutics 229(1):132-138 (1984)
	C7	Harris, M. C. et al., "Sequential N-Arylation of Primary Amines as a Route to Alkylidylamines," J. Org. Chem. 64:6019-6022 (1999)
	C8	Hrib, N. J., et al., "The dopamine D ₄ receptor: a controversial therapeutic target," Drugs of the Future 2000 25(6):587-611
	C9	Koch, V. et al., "Chemistry of 3-Hydroxypyridien part 2: Synthesis of 5,6-Dihalo-3hydroxypyridines," Synthesis 499-501 (1990)
	C10	Lissoni, et al., "Efficacy of bromocriptine in the treatment of metastatic breast cancer- and prostate cancer-related hyperprolactinemia," Neuroendocrinology Letters ISSN 21:405-408 (2000)
	C11	Lynch, J.K. et al., "Efficient asymmetric synthesis of ABT-594; a potent, orally effective analgesic," Tetrahedron: Asymmetry 9:2791-2794 (1998)
	C12	Melis, M et al., "Dopamine and Sexual Behavior," Neuroscience and Biobehavioral Reviews, 19(1):193-35 (1995)
	C13	Milligan, G. et al., "Chimaeric G proteins: their potential use in drug discovery," Trends Pharmacol Sci 20:118-124 (1998)
	C14	Missale, C. et al. "Dopamine receptors: from structure to function," Physiol Rev 78:189-225 (1998)
	C15	Morales, A. et al., "Oral and Topical Treatment of Erectile Dysfunction: present and future," Urologic Clinics of North America, vol. 22:879-886 (1995)

EXAMINER

L. Bernhardt

DATE CONSIDERED

9/30/05

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)

DATE: March 12, 2003

SHEET 3 of 3

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98 (b))	ATTY. DOCKET NO. 6789.US.03	SERIAL NO. (not yet assigned)
	APPLICANT(S) M. D. Cowart, et al.	
	FILING DATE September 5, 2003	GROUP (not yet assigned)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

DOCUMENT NUMBER	PUBLICA- TION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO


OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

<i>EB</i>	C16	Moreland, RB, et al., "Prospectives for Pharmacotherapy of Male Erectile Dysfunction," Curr Opinion CPNS Invest Drugs, 2:283-302 (2000)
<i>f</i>	C17	Primus, R. et al., "Localization and characterization of dopamine D ₄ binding sites in rat and human brain by use of the novel D ₄ receptor-selective ligand [³ H]NGD 94-1," J. Pharmacol Exp. Ther 282:1020-1027 (1997)
	C18	Suzuki, M. et al., "D ₃ dopamine receptor mRNA is widely express in human brain," Brian Res 779:58-74 (1998)
	C19	Vallone, D. et al., "Structure and function of dopamine receptors," Neurosci Biobehav. Rev. 24:125-132 (2000)
	C20	Wagaw, S. et al., "The Synthesis of Aminopyridines: A Method Employing Palladium-Catalyzed Carbon-Nitrogen Bond Formation," J. Org. Chem 61:7240-7241 (1996)
	C21	Yang B. et al., "Palladium-catalyzed amination of aryl halides and sulfonates," Journal of Organometallic Chemistry 576:125-146 (1999)
	C22	Bevilacqua et al., "Pharmacology for erectile dysfunction" TIPS 21:484-489(2000)
	C23	Shvedov et al., "Catalytic alkylation of amines with alcohols", Zhurnal Organicheskoi Khimii 6(9): 1883-1840 (1970)
<i>↓</i>	C24	Pugsley et al., "The discovery of PD89211 and related compounds: selective dopamine D ₄ receptor antagonists," Progress in Neuro-Psychopharmacology & biological Psychiatry 26(2):219-226 (2002)

EXAMINER <i>L Bernhardt</i>	DATE CONSIDERED <i>9/30/03</i>
---------------------------------------	--

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)



DATE: May 10, 2005

SHEET 1 of 1

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))

ATTY. DOCKET NO.

6789.US.O3

SERIAL NO.

10/656,672

APPLICANT(S)

M. D. Cowart, et al.

FILING DATE

September 5, 2003

GROUP

1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	DOCUMENT NUMBER	PUBLIC- ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO
FB	B1 94/22839	13.10.94	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

FB	C1	Berge, S.M. et al., J. Pharmaceutical Sciences 66:1et seq (1977)
FB	C2	Padma-Nathan, H. et al., "Efficacy and safety of apomorphine SL vs. placebo for male erectile dysfunction," Urology 161:214 (abstract 821) (1999)
FB	C3	Sule, D.P. et al., "Synthesis and Anthelmintic activity of 2-(N4-Substituted-N1-Piperazinyl) Methyl 5-(or 6) - substituted benzimidazoles," Bull. Haffkine Inst. 6(2):62-64 (1978)
FB	C4	"IUPAC 1974 Recommendation for Section E, Fundamental Stereochemistry," Pure Appl. Chem. 45:13-30 (1976)

EXAMINER

FB Benhuda

DATE CONSIDERED

9/30/05

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)